Fentanyl (FYL) Rapid Test

• Fentanyl is classified as a synthetic opioid. It is used medically under controlled prescription conditions, but illicitly made fentanyl is a major public health concern because it may be mixed into counterfeit tablets or other substances without a person’s knowledge.
• For employers, treatment centers, hospitals, laboratories, and public health programs, fentanyl testing helps support workplace safety screening, rehabilitation monitoring, clinical toxicology screening, post-incident testing, drug abuse prevention programs, and forensic testing workflows.
• The Fentanyl (FYL) Rapid Test by LARKSOIS Pharma provides a convenient first-level screening method where quick decision support is needed.

• The Fentanyl (FYL) Rapid Test uses an immunoassay-based rapid testing method. When urine is applied to the test device, the sample migrates across the test membrane and reacts with fentanyl-specific reagents.
• The result is visually interpreted according to the instructions supplied with the product.
• This type of test is designed to provide a preliminary screening result, not a final laboratory diagnosis. A positive or non-negative rapid test result should always be reviewed with confirmatory testing, particularly when results may affect employment, treatment, legal, or clinical decisions.

Urine is one of the most widely used specimens for drug abuse screening because it is non-invasive, easy to collect, and practical for routine testing programs. LARKSOIS Pharma’s Fentanyl (FYL) Rapid Test is developed for urine specimen testing and should be used according to the product insert, sample handling instructions, and applicable testing regulations.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, forensic, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The 200ng/ml cut-off indicates the screening threshold used by this product. If the fentanyl-related concentration in the urine sample meets or exceeds the test threshold, the device may show a presumptive positive result. If the concentration is below the cut-off, the test may show a negative result. Results may be influenced by sample quality, testing conditions, individual metabolism, timing of exposure, and cross-reactivity, so confirmatory testing is recommended for all non-negative results.

Instructions

• Rapid urine-based screening format
• Designed for fentanyl drug abuse testing
• 200ng/ml cut-off level
• Simple visual result interpretation
• Suitable for professional testing environments
• Supports workplace, clinical, rehabilitation, and forensic screening
• Compact and easy-to-store product format
• Manufactured with international-quality standards
• Useful for single-drug or multi-panel drug testing programs

The Fentanyl (FYL) Rapid Test by LARKSOIS Pharma can be used across multiple professional settings where preliminary fentanyl screening support is required.

Applications

• Workplace drug testing
• Rehabilitation and recovery monitoring
• Clinical toxicology screening
• Post-incident testing
• Drug abuse prevention programs
• Forensic and institutional testing workflows
• Public safety screening programs
• International diagnostic product distribution

Positive

A positive or non-negative result suggests that fentanyl-related compounds may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method.

Negative

A negative result suggests that fentanyl-related compounds were not detected or were below the cut-off at the time of testing. A negative result does not always rule out exposure if testing is done outside the detection period or if the concentration is below the cut-off.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Fentanyl (FYL) Rapid Test.

Instructions

• Store in a cool, dry place
• Keep away from direct sunlight and moisture
• Do not freeze the test kit
• Use before the expiry date printed on the packaging
• Keep the test sealed until use
• Avoid using damaged or opened pouches

Instructions

• For professional in-vitro screening use only
• Use only urine specimens as specified
• Do not reuse the test device
• Follow the product insert carefully
• Handle all specimens as potentially infectious
• Wear appropriate protective equipment during testing
• Do not interpret results after the recommended reading time
• Confirm non-negative results using laboratory-based testing
• Keep the product away from children and unauthorized users

LARKSOIS Pharma focuses on dependable diagnostic and pharmaceutical product solutions for international markets. The Fentanyl (FYL) Rapid Test reflects the brand’s commitment to quality, usability, and global healthcare support.

Advantages

• International product quality approach
• Drug of abuse rapid testing portfolio
• Professional-use screening solutions
• Reliable packaging and documentation support
• Suitable for bulk and institutional requirements
• Customer-focused supply for global markets
• Reliable source for rapid drug testing products